222 related articles for article (PubMed ID: 10980849)
21. Efficacy and safety of statin and fibrate combination therapy in lipid management.
Kota SK; Meher LK; Rao ES; Jammula S; Modi KD
Diabetes Metab Syndr; 2012; 6(3):173-4. PubMed ID: 23158983
[TBL] [Abstract][Full Text] [Related]
22. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
23. Clinical update on the use of niacin for the treatment of dyslipidemia.
Berra K
J Am Acad Nurse Pract; 2004 Dec; 16(12):526-34. PubMed ID: 15645997
[TBL] [Abstract][Full Text] [Related]
24. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
Crouse JR
Coron Artery Dis; 1996 Apr; 7(4):321-6. PubMed ID: 8853585
[TBL] [Abstract][Full Text] [Related]
25. Niacin for dyslipidemia: considerations in product selection.
McKenney J
Am J Health Syst Pharm; 2003 May; 60(10):995-1005. PubMed ID: 12789870
[TBL] [Abstract][Full Text] [Related]
26. Myopathy with statin-fibrate combination therapy: clinical considerations.
Jacobson TA
Nat Rev Endocrinol; 2009 Sep; 5(9):507-18. PubMed ID: 19636324
[TBL] [Abstract][Full Text] [Related]
27. Statin induced myotoxicity.
Sathasivam S
Eur J Intern Med; 2012 Jun; 23(4):317-24. PubMed ID: 22560377
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of dyslipidemia.
McKenney JM
Cardiovasc Drugs Ther; 2001 Sep; 15(5):413-22. PubMed ID: 11855660
[TBL] [Abstract][Full Text] [Related]
29. [Niacin--an additive therapeutic approach for optimizing lipid profile].
Wieneke H; Schmermund A; Erbel R
Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
[TBL] [Abstract][Full Text] [Related]
30. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
32. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
Gupta EK; Ito MK
Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
[TBL] [Abstract][Full Text] [Related]
33. [Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents].
Franc S; Bruckert E; Giral P; Turpin G
Presse Med; 1997 Dec; 26(38):1855-8. PubMed ID: 9569908
[TBL] [Abstract][Full Text] [Related]
34. A case for immediate-release niacin.
Bassan M
Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
[TBL] [Abstract][Full Text] [Related]
35. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
36. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
[TBL] [Abstract][Full Text] [Related]
37. [Drug combination therapies for patients with hyperlipidemia and its significance].
Onuma T; Kawamori R
Nihon Rinsho; 2001 Mar; 59 Suppl 3():566-71. PubMed ID: 11347133
[No Abstract] [Full Text] [Related]
38. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
39. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
Forcadell-Peris MJ; de Diego-Cabanes C
Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
[TBL] [Abstract][Full Text] [Related]
40. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
